Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies Inc. (BIAFW) pioneers noninvasive diagnostic solutions for early cancer detection, with a focus on improving patient outcomes through innovations like its CyPath Lung test. This page aggregates official company announcements, clinical milestones, and strategic developments for stakeholders tracking advancements in precision diagnostics.
Access timely updates on regulatory progress, partnership agreements, and research breakthroughs directly from the source. Our curated news feed includes earnings reports, product launch details, and peer-reviewed study results relevant to bioAffinity’s proprietary flow cytometry technologies.
Key coverage areas include diagnostic accuracy validations, licensing agreements with healthcare providers, and advancements in cellular analysis methodologies. Investors and researchers alike benefit from centralized access to verified information supporting data-driven decisions.
Bookmark this page for streamlined tracking of bioAffinity’s contributions to reducing invasive procedures in cancer care. Check regularly for authoritative updates on technologies reshaping modern diagnostics.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) reports an increase in sales of CyPath® Lung, their noninvasive diagnostic test for lung cancer detection. April sales were up 21% from March, with new orders from physicians in various states. The company also welcomed new team members to support the CyPath® Lung product launch. Additionally, bioAffinity will present research at the American Thoracic Society's Annual Conference.
FAQ
What is the current stock price of bioAffinity Tech (BIAFW)?
